story of the week
Dapagliflozin Reduces Risk of Worsening Heart Failure or Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA: The Journal of the American Medical Association
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
JAMA 2020 Mar 27;[EPub Ahead of Print], MC Petrie, S Verma, KF Docherty, SE Inzucchi, I Anand, J Belohlávek, M Böhm, CE Chiang, VK Chopra, RA de Boer, AS Desai, M Diez, J Drozdz, A Dukát, J Ge, J Howlett, T Katova, M Kitakaze, CEA Ljungman, B Merkely, JC Nicolau, E O'Meara, PN Vinh, M Schou, S Tereshchenko, L Køber, MN Kosiborod, AM Langkilde, FA Martinez, P Ponikowski, MS Sabatine, M Sjöstrand, SD Solomon, P Johanson, PJ Greasley, D Boulton, O Bengtsson, PS Jhund, JJV McMurrayFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.